Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03650257Phase 2Unknown

A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Role: lead

NCT04206254Phase 2Unknown

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer

Role: lead

NCT02122822Phase 1Completed

Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Role: lead

NCT02317471Phase 1Unknown

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

Role: collaborator

NCT02133079Phase 1Unknown

Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96

Role: lead

All 5 trials loaded